🇺🇸 FDA

Intelligence · Clinical Pipeline

GSK Glaxo Smith Pipeline

All ClinicalTrials.gov programs at GSK Glaxo Smith — phase, modality, and trial IDs.

Programs
205

Quick answer

GSK Glaxo Smith has 205 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Meningococcal vaccine GSK134612

    GlaxoSmithKline

    Infections, Meningococcal

    phase 3 mab completed

    2 trials

  2. Nimenrix

    GlaxoSmithKline

    Infections, Meningococcal

    phase 3 mab completed

    1 trial

  3. Niraparib

    GlaxoSmithKline

    Neoplasms, Breast

    phase 3 small molecule active

    1 trial

  4. Niraparib Placebo Tablets

    GlaxoSmithKline

    Neoplasms, Breast

    phase 3 small molecule active

    1 trial

  5. Niraparib Placebo Tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  6. Novolizer Salbutamol 100 microgrammes/dose, poudre pour inhalation, Sterile 0.9% (w/v) sodium chloride solution in single-use PFS

    GlaxoSmithKline

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  7. PREDNISOLONE, Placebo for Depemokimab Injection, Placebo for Prednisolone

    GlaxoSmithKline

    Hypereosinophilic Syndrome (HES)

    phase 3 small molecule active

    1 trial

  8. Placebo

    GlaxoSmithKline

    Infections, Papillomavirus

    phase 3 mab completed

    1 trial

  9. Placebo for Belimumab Solution for Injection, 200 mg/mL, Benlysta 200 mg solution for injection in pre-filled syringe.

    GlaxoSmithKline

    systemic sclerosis associated interstitial lung disease

    phase 3 small molecule active

    1 trial

  10. Placebo for Bepirovirsen Solution for Injection 150 mg/mL

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 3 small molecule active

    1 trial

  11. Placebo for Bepirovirsen Solution for Injection 150 mg/mL

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 3 small molecule active

    1 trial

  12. Placebo for Mepolizumab Injection, MEPOLIZUMAB, Placebo for Depemokimab Injection

    GlaxoSmithKline

    Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy

    phase 3 small molecule active

    1 trial

  13. Priorix - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze|Masern-Mumps-Röteln-Lebendimpfstoff, Priorix - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze|Masern-Mumps-Röteln-Lebendimpfstoff, VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff, Priorix - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze|Masern-Mumps-Röteln

    GlaxoSmithKline

    Varicella

    phase 3 small molecule active

    1 trial

  14. RSV MAT

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 mab terminated

    1 trial

  15. Rosiglitazone Extended Release 2mg

    GlaxoSmithKline

    Alzheimer's Disease

    phase 3 small molecule completed

    1 trial

  16. SB-497115-GR 12.5mg

    GlaxoSmithKline

    Chronic Idiopathic Thrombocytopenic Purpura

    phase 3 small molecule completed

    1 trial

  17. Salbutamol HFA-134a

    GlaxoSmithKline

    Asthma

    phase 3 small molecule completed

    1 trial

  18. Sterile 0.9% (w/v) sodium chloride solution in single-use PFS, Novolizer Salbutamol 100 microgrammes/dose, poudre pour inhalation

    GlaxoSmithKline

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  19. TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion, TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion

    GlaxoSmithKline

    Neoplasms, Lung

    phase 3 small molecule active

    1 trial

  20. Tafenoquine

    GlaxoSmithKline

    Malaria, Vivax

    phase 3 small molecule completed

    2 trials

  21. The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub study

    GlaxoSmithKline

    Asthma with type 2 inflammation characterized by an eosinophilic phenotype

    phase 3 other active

    1 trial

  22. Tritanrix-HepB/Hib-MenAC

    GlaxoSmithKline

    Whole Cell Pertussis

    phase 3 mab completed

    1 trial

  23. Tritanrix™-HepB/Hiberix™ Kft.

    GlaxoSmithKline

    Whole Cell Pertussis

    phase 3 mab completed

    1 trial

  24. VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff, VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff

    GlaxoSmithKline

    Varicella

    phase 3 small molecule active

    1 trial

  25. VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff, VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff

    GlaxoSmithKline

    Varicella

    phase 3 small molecule active

    1 trial

  26. VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff, VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff

    GlaxoSmithKline

    Varicella

    phase 3 small molecule active

    1 trial

  27. Ventolin 100 microgramos/inhalación suspensión para inhalación en envase a presión* (*) sin CFC

    GlaxoSmithKline

    Asthma

    phase 3 small molecule active

    1 trial

  28. Zelvina 5 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Revlimid 25 mg hard capsules, Zelvina 10 mg hard capsules, Revlimid 5 mg hard capsules, Dexamethason 8 mg GALEN® Tabletten, Revlimid 10 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Zelvina 25 mg hard capsules, DARZALEX 1800 mg solution for injection

    GlaxoSmithKline

    Multiple myeloma

    phase 3 small molecule active

    1 trial

  29. albiglutide + insulin glargine

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

    phase 3 mab completed

    1 trial

  30. alosetron

    GlaxoSmithKline

    Irritable Colon

    phase 3 small molecule completed

    1 trial

  31. denosumab

    GlaxoSmithKline

    Osteoporosis, Postmenopausal

    phase 3 small molecule completed

    1 trial

  32. dutasteride 0.5mg once daily for 4 years

    GlaxoSmithKline

    Prostatic Hyperplasia

    phase 3 small molecule completed

    1 trial

  33. eltrombopag

    GlaxoSmithKline

    Purpura, Thrombocytopaenic, Idiopathic

    phase 3 small molecule completed

    2 trials

  34. eltrombopag

    GlaxoSmithKline

    Hepatitis C, Chronic

    phase 3 small molecule completed

    1 trial

  35. fluticasone furoate/vilanterol

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 3 small molecule completed

    1 trial

  36. lamotrigine, 300 mg/day

    GlaxoSmithKline

    Epilepsy, Partial

    phase 3 small molecule completed

    1 trial

  37. lapatinib

    GlaxoSmithKline

    Neoplasms, Breast

    phase 3 small molecule completed

    1 trial

  38. placebo to match albiglutide

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  39. 0.9% Sodium Chloride Injection

    GlaxoSmithKline

    Non-alcoholic Fatty Liver Disease

    phase 2 small molecule active

    1 trial

  40. A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults with Alcohol-related Liver Disease (ALD)

    GlaxoSmithKline

    Liver Diseases, Alcoholic

    phase 2 other active

    1 trial

  41. A Multi-Center, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 [AL101] in Participants with Early Alzheimer’s Disease.

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 other active

    1 trial

  42. A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of GSK5458514 PSMA targeting T cell engager alone or in combination with other anti-cancer agents in adult participants with metastatic castration-resistant prostate cancer (mCRPC)

    GlaxoSmithKline

    Neoplasms, Prostate

    phase 2 other active

    1 trial

  43. A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 2 other active

    1 trial

  44. A Phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 alone and in combination in participants with previously treated advanced unresectable or metastatic gastrointestinal solid tumors

    GlaxoSmithKline

    Gastrointestinal Neoplasms

    phase 2 other active

    1 trial

  45. A Phase 2, Randomized, Open-label, Study of Momelotinib in Participants with Anemia due to Low-risk Myelodysplastic Syndrome.

    GlaxoSmithKline

    Myelodysplastic Syndrome

    phase 2 other active

    1 trial

  46. A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants with Relapsed or Refractory Multiple Myeloma (DREAMM-14)

    GlaxoSmithKline

    Multiple Myeloma

    phase 2 other active

    1 trial

  47. A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects with Advanced Solid Tumors

    GlaxoSmithKline

    Ovarian Neoplasms

    phase 2 other active

    1 trial

  48. A prospective, multi-centre study (B-Sure) to evaluate long-term durability of treatment response in chronic hepatitis B participants with and without nucleos(t)ide therapy who have participated in a previous bepirovirsen treatment study.

    GlaxoSmithKline

    Chronic Hepatitis B

    phase 2 other active

    1 trial

Frequently asked questions

How many pipeline programs does GSK Glaxo Smith have?

205 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.